Using MRI to improve prostate cancer diagnosis with targeted biopsies
Magnetic Resonance Imaging (MRI) Derived Quantitative Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
This study is testing a new software that uses MRI scans to help doctors better diagnose prostate cancer and guide treatment decisions for patients.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 180 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | University of Chicago Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Chicago, Illinois) |
| Trial ID | NCT05710380 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate a software developed by researchers at the University of Chicago that analyzes MRI images of the prostate to enhance the diagnosis of prostate cancer. Participants will undergo a one-time MRI and 1-2 MRI-guided biopsies, followed by a 12-month follow-up to monitor their progress. The goal is to create risk maps that can assist in making more informed decisions regarding prostate cancer diagnosis and treatment.
Who should consider this trial
Good fit: Ideal candidates are patients with known or suspected prostate cancer who are scheduled for a diagnostic MRI exam.
Not a fit: Patients who have previously undergone treatments for prostate cancer or those unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate diagnoses of prostate cancer, potentially improving patient outcomes.
How similar studies have performed: Other studies have shown promise in using MRI-guided biopsies for prostate cancer diagnosis, indicating that this approach is supported by prior research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with known or suspected prostate cancer who have been referred for a diagnostic magnetic resonance imaging (MRI) exam of the prostate, to be followed by an MRI-guided fusion biopsy of the prostate. * Voluntary written informed consent before the MRI examination. Exclusion Criteria: * Subjects incapable of giving informed written consent. * Subjects who cannot adhere to the experimental protocols for any reason, or have an inability to communicate with the researcher; * Subjects with psychiatric disorders that affect their ability to consent for themselves will be excluded and not the entire population of patients with psychiatric disorders. * Prisoners. * Minor children (under the age of 18 years old). * Patients with previous treatments (surgery, radiation, focal ablation, hormone or other chemotherapy) for prostate cancer.
Where this trial is running
Chicago, Illinois
- University of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois, United States (Recruiting)
Study contacts
- Study coordinator: Aytekin Oto, MD
- Email: aoto@radiology.bsd.uchicago.edu
- Phone: 773-702-8553
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.